Biora Therapeutics, Inc. - Common Stock (BIOR)

$0.73 0.00 (0.00%)

16:00 EDT BIOR Stock Quote Delayed 30 Minutes

BIOR Stock Earnings: Biora Therapeutics Misses EPS for Q4 2023

By InvestorPlace Earnings Mar 26, 2024

BIOR stock results show that Biora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Hidden Gems: 3 Penny Stocks Flying Under the Radar.

3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024

More Articles

Volume:

Previous Close -

Market Cap 2.97M

PE Ratio -14.62

EPS -0.05

Volume (Avg. Vol.) 100

Day's Range -

52-Week Range $0.59 - $6.70

Dividend & Yield N/A (N/A)

BIOR Stock Predictions, Articles, and Biora Therapeutics, Inc. - Common Stock News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jan 13, 2023

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jan 12, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?

By William White, InvestorPlace Writer Jan 11, 2023

Biora Therapeutics (BIOR) stock is on the rise Wednesday following news of feedback from the U.S. Food and Drug Administration (FDA).

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jan 11, 2023

It's time to start off the day with a breakdown of the biggest pre-market stock movers making the news on Wednesday morning!

BIOR Stock Starts Trading as Progenity’s Rebrand Takes Shape. What to Know.

By Larry Ramer, InvestorPlace Contributor May 10, 2022

Biora's product is supposed to enable biologics to be delivered directly to GI tracts. BIOR stock is a favorite of retail investors.

Biora Therapeutics to sell 71.07M shares for holders (NASDAQ:BIOR)

From Seeking Alpha Dec 22, 2023

Biora Therapeutics (BIOR) files prospectus for proposed resale of 71.07M shares by selling stockholders.

FDA clears Biora to begin Phase 1 testing of ulcerative colitis treatment (BIOR)

From Seeking Alpha Nov 30, 2023

Biora (BIOR) said that it has received FDA clearance to begin Phase 1 testing of its drug/device combination BT-600 for the treatment of ulcerative colitis. Read more here.

Biora submits updated IND application to FDA for BT-600 (NASDAQ:BIOR)

From Seeking Alpha Oct 30, 2023

Biota Therapeutics (BIOR) has submitted an updated IND for BT-600, its product candidate to treat ulcerative colitis. Read more here.

Biora IND for BT-600 delayed due to FDA request for more info (BIOR)

From Seeking Alpha Oct 23, 2023

Biora Therapeutics (BIOR) said its Investigational New Drug application for BT-600 has been delayed due to an FDA request for more information. Read more here.

Biora Therapeutics reduces debt by $50M, largest shareholder increases equity exposure

From Seeking Alpha Sep 19, 2023

Biora Therapeutics (BIOR) soared +10.04% premarket to $2.3 on Tuesday as the biotech firm announced an agreement with certain funds managed by Athyrium Capital Management to...

Biora Therapeutics (BIOR) Gets a Buy from H.C. Wainwright

From TipRanks Nov 15, 2022

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics (BIOR – Research Report), with a price target ...

ADVERTISEMENT